Review

Therapy for Obesity Based on Gastrointestinal Hormones

Jonatan I. Bagger, Mikkel Christensen, Filip K. Knop, Tina Vilsboll

Manuscript submitted September 24, 2011; resubmitted October 24, 2011; accepted October 28, 2011.

Keywords: DPP-4 inhibitors, GLP-1 receptor agonist, incretin hormone, obesity, type 2 diabetes

Abstract

It has long been known that peptide hormones from the gastrointestinal tract have significant impact on the regulation of nutrient metabolism. Among these hormones, incretins have been found to increase insulin secretion, and thus incretin-based therapies have emerged as new modalities for the treatment of type 2 diabetes. In contrast to other antidiabetic treatments, these agents have a positive outcome profile on body weight. Worldwide there are 500 million obese people, and 3 million are dying every year from obesity-related diseases. Recently, incretin-based therapy was proposed for the treatment of obesity. Currently two different incretin therapies are widely used in the treatment of type 2 diabetes: 1) the GLP-1 receptor agonists which cause significant and sustained weight loss in overweight patients, and 2) dipeptidyl peptidase 4 (DPP-4) inhibitors being weight neutral. These findings have led to a greater interest in the physiology of intestinal peptides with potential weight-reducing properties. This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity.

Fulltext: HTML , PDF (143KB)

This article has been cited by other articles:

	Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Morano S, Romagnoli E, Filardi T, Nieddu L, Mandosi E, Fallarino M, Turinese I, Dagostino MP, Lenzi A, Carnevale V Acta Diabetol 2015. In press
	Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial Larsen JR, Vedtofte L, Holst JJ, Oturai P, Kjaer A, Corell CU, Vilsboll T, Fink-Jensen A Bmj Open 2014. 4(3):e004227
	The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, Ito S Endocr J 2012. 59(10):889-894
	The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS Special Issue Raz I, Gallwitz B Rev Diabet Stud 2011. 8(3):288-292